Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas

  • Jane Houldsworth
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Adam B. Olshen
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Giorgio Cattoretti
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Gerard B. Donnelly
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Julie Teruya-Feldstein
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Jing Qin
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Nallasivam Palanisamy
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Yingjing Shen
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Katerina Dyomina
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Marina Petlakh
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Qiulu Pan
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Andrew D. Zelenetz
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • Riccardo Dalla-Favera
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.
  • R. S. K. Chaganti
    From the Cell Biology Program, Departments of Epidemiology and Biostatistics, Medicine, and Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY; the Institute for Cancer Genetics, Columbia University, New York, NY; and Cancer Genetics Inc, Milford, MA.

抄録

<jats:title>Abstract</jats:title><jats:p>Although it has been suggested that REL is the critical target gene of 2p12-16 amplification in diffuse large B-cell lymphoma (DLBCL), little experimental evidence supports this notion. In the present study, we sought to evaluate the relationship between REL amplification and REL function in a panel of 46 newly diagnosed DLBCLs and to correlate with DLBCL subgroups as identified by gene expression profiles and clinical features. The results indicate that amplification of the REL locus is not associated with accumulation of the active form of REL, as evaluated by immunofluorescence analysis. Upon subgrouping of the DLBCL cases based on gene expression signatures, REL amplification was detected in all subgroups, while high levels of nuclear-located REL were more frequently detected in activated B-cell–like DLBCL. Correlative analyses of REL copy number and REL nuclear accumulation with clinical parameters did not reveal any significant associations. Together these results indicate that 2p12-16 amplification does not lead to abnormal REL activation, suggesting that REL may not be the functional target of the amplification event. Nonetheless, these data indicate that DLBCLs are heterogeneous with respect to REL and thus nuclear factor–κB (NF-κB) activity.</jats:p>

収録刊行物

  • Blood

    Blood 103 (5), 1862-1868, 2004-03-01

    American Society of Hematology

被引用文献 (2)*注記

もっと見る

詳細情報

問題の指摘

ページトップへ